Metraipolis › archive › dc_4b28df594df3

Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women — Europe PMC PMID:41484973

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41484973
DOI
10.1186/s13293-[numero omesso]-1
License (as archived)
solo-consultazione
Archived
2026-11-07T02:30:43.249Z
SHA-256 of the archived text
fda8faf28d7f4b2b2b19027226bfde6eda492c1214044a674e37176e87290b72
Stable URL of this page
https://metraipolis.com/documento/dc_4b28df594df3

How to cite

Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women — Europe PMC PMID:41484973 — Europe PMC (en), https://europepmc.org/article/MED/41484973 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4b28df594df3 (Metraipolis archive dc_4b28df594df3, sha256 fda8faf28d7f4b2b2b19027226bfde6eda492c1214044a674e37176e87290b72)
BibTeX
@misc{dc4b28df594df3,
  title = {Real-world evidence indicates romosozumab use is associated with a greater reduction in osteoporotic fractures than PTH (1-34) analogs in women — Europe PMC PMID:41484973},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41484973},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4b28df594df3; sha256 fda8faf28d7f4b2b2b19027226bfde6eda492c1214044a674e37176e87290b72},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41484973. Agents can read the archived copy with the MCP tool read_document.